IRIS Accounts Production v25.1.3.33 14545840 Board of Directors Board of Directors Board of Directors 1.1.24 31.12.24 31.12.24 false true false false false true false iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh145458402023-12-31145458402024-12-31145458402024-01-012024-12-31145458402022-12-15145458402022-12-162023-12-31145458402023-12-3114545840ns15:EnglandWales2024-01-012024-12-3114545840ns14:PoundSterling2024-01-012024-12-3114545840ns10:Director12024-01-012024-12-3114545840ns10:Director22024-01-012024-12-3114545840ns10:Director32024-01-012024-12-3114545840ns10:PrivateLimitedCompanyLtd2024-01-012024-12-3114545840ns10:SmallEntities2024-01-012024-12-3114545840ns10:AuditExempt-NoAccountantsReport2024-01-012024-12-3114545840ns10:SmallCompaniesRegimeForDirectorsReport2024-01-012024-12-3114545840ns10:SmallCompaniesRegimeForAccounts2024-01-012024-12-3114545840ns10:FullAccounts2024-01-012024-12-311454584012024-01-012024-12-3114545840ns5:CurrentFinancialInstruments2024-12-3114545840ns5:CurrentFinancialInstruments2023-12-3114545840ns5:Non-currentFinancialInstruments2024-12-3114545840ns5:Non-currentFinancialInstruments2023-12-3114545840ns5:ShareCapital2024-12-3114545840ns5:ShareCapital2023-12-3114545840ns5:RetainedEarningsAccumulatedLosses2024-12-3114545840ns5:RetainedEarningsAccumulatedLosses2023-12-3114545840ns10:RegisteredOffice2024-01-012024-12-3114545840ns5:IntangibleAssetsOtherThanGoodwill2024-01-012024-12-3114545840ns5:PatentsTrademarksLicencesConcessionsSimilar2024-01-012024-12-3114545840ns5:IntangibleAssetsOtherThanGoodwill2023-12-3114545840ns5:IntangibleAssetsOtherThanGoodwill2024-12-3114545840ns5:IntangibleAssetsOtherThanGoodwill2023-12-3114545840ns5:PlantMachinery2023-12-3114545840ns5:PlantMachinery2024-01-012024-12-3114545840ns5:PlantMachinery2024-12-3114545840ns5:PlantMachinery2023-12-3114545840ns5:PlantMachineryns5:LeasedAssetsHeldAsLessee2024-01-012024-12-3114545840ns5:PlantMachineryns5:LeasedAssetsHeldAsLessee2024-12-3114545840ns5:WithinOneYearns5:CurrentFinancialInstruments2024-12-3114545840ns5:WithinOneYearns5:CurrentFinancialInstruments2023-12-31
REGISTERED NUMBER: 14545840 (England and Wales)














UNAUDITED FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 DECEMBER 2024

FOR

SANDFIELDS PHARMA LTD

SANDFIELDS PHARMA LTD (REGISTERED NUMBER: 14545840)






CONTENTS OF THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024




Page

Balance Sheet 1

Notes to the Financial Statements 3


SANDFIELDS PHARMA LTD (REGISTERED NUMBER: 14545840)

BALANCE SHEET
31 DECEMBER 2024

31/12/24 31/12/23
Notes £    £    £   
FIXED ASSETS
Intangible assets 4 303,397 222,062
Tangible assets 5 9,088 3,151
312,485 225,213

CURRENT ASSETS
Stocks 93,786 53,898
Debtors 6 240,201 171,826
Cash at bank and in hand 99,288 154,236
433,275 379,960
CREDITORS
Amounts falling due within one year 7 493,383 456,207
NET CURRENT LIABILITIES (60,108 ) (76,247 )
TOTAL ASSETS LESS CURRENT
LIABILITIES

252,377

148,966

CREDITORS
Amounts falling due after more than one year 8 (6,272 ) -

PROVISIONS FOR LIABILITIES (670 ) (788 )
NET ASSETS 245,435 148,178

CAPITAL AND RESERVES
Called up share capital 10 12 6
Retained earnings 245,423 148,172
SHAREHOLDERS' FUNDS 245,435 148,178

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 December 2024.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 December 2024 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

SANDFIELDS PHARMA LTD (REGISTERED NUMBER: 14545840)

BALANCE SHEET - continued
31 DECEMBER 2024


The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 15 May 2025 and were signed on its behalf by:




Mr A Edwards - Director Mrs S L Perrington - Director




Mr C R Perrington - Director


SANDFIELDS PHARMA LTD (REGISTERED NUMBER: 14545840)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024

1. STATUTORY INFORMATION

Sandfields Pharma LTD is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address are as below:

Registered number: 14545840

Registered office: Ynys Corrwg Farm
Glyncorrwg
Port Talbot
SA13 3AA

2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Turnover
Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

Intangible assets
Intangible assets are initially measured at cost. After initial recognition, intangible assets are measured at cost less any accumulated amortisation and any accumulated impairment losses.

Patents and licences are being amortised evenly over their estimated useful life of fifteen years.

Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life or, if held under a finance lease, over the lease term, whichever is the shorter.

Stocks
Stocks are valued at the lower of cost and net realisable value, after making due allowance for obsolete and slow moving items.

Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.


SANDFIELDS PHARMA LTD (REGISTERED NUMBER: 14545840)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 DECEMBER 2024

2. ACCOUNTING POLICIES - continued
Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Hire purchase and leasing commitments
Assets obtained under hire purchase contracts or finance leases are capitalised in the balance sheet. Those held under hire purchase contracts are depreciated over their estimated useful lives. Those held under finance leases are depreciated over their estimated useful lives or the lease term, whichever is the shorter.

The interest element of these obligations is charged to profit or loss over the relevant period. The capital element of the future payments is treated as a liability.

Pension costs and other post-retirement benefits
The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 15 (2023 - 9 ) .

4. INTANGIBLE FIXED ASSETS
Other
intangible
assets
£   
COST
At 1 January 2024 237,500
Additions 103,500
At 31 December 2024 341,000
AMORTISATION
At 1 January 2024 15,438
Charge for year 22,165
At 31 December 2024 37,603
NET BOOK VALUE
At 31 December 2024 303,397
At 31 December 2023 222,062

SANDFIELDS PHARMA LTD (REGISTERED NUMBER: 14545840)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 DECEMBER 2024

5. TANGIBLE FIXED ASSETS
Plant and
machinery
etc
£   
COST
At 1 January 2024 3,707
Additions 9,917
Disposals (2,795 )
At 31 December 2024 10,829
DEPRECIATION
At 1 January 2024 556
Charge for year 1,604
Eliminated on disposal (419 )
At 31 December 2024 1,741
NET BOOK VALUE
At 31 December 2024 9,088
At 31 December 2023 3,151

Fixed assets, included in the above, which are held under hire purchase contracts are as follows:

Plant and
machinery
etc
£   
COST
Additions 9,917
At 31 December 2024 9,917
DEPRECIATION
Charge for year 1,488
At 31 December 2024 1,488
NET BOOK VALUE
At 31 December 2024 8,429

6. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
31/12/24 31/12/23
£    £   
Trade debtors 183,319 124,474
Other debtors 56,882 47,352
240,201 171,826

SANDFIELDS PHARMA LTD (REGISTERED NUMBER: 14545840)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 DECEMBER 2024

7. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
31/12/24 31/12/23
£    £   
Hire purchase contracts 2,091 -
Trade creditors 239,040 155,757
Taxation and social security 91,621 45,138
Other creditors 160,631 255,312
493,383 456,207

8. CREDITORS: AMOUNTS FALLING DUE AFTER MORE THAN ONE YEAR
31/12/24 31/12/23
£    £   
Hire purchase contracts 6,272 -

9. SECURED DEBTS

The following secured debts are included within creditors:

31/12/24 31/12/23
£    £   
Hire purchase contracts 8,363 -

10. CALLED UP SHARE CAPITAL

Allotted, issued and fully paid:
Number: Class: Nominal 31/12/24 31/12/23
value: £ £
6 Ordinary Shares £1 6 6
1 Ordinary A Shares £1 1
1 Ordinary B Shares £1 1
1 Ordinary C Shares £1 1
1 Ordinary D Shares £1 1
1 Ordinary E Shares £1 1
1 Ordinary F Shares £1 1


12 6